ATP6V1H Knockout cell line (HeLa)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

The HeLa cell line is a globally utilized immortal human cervical cancer cell line, historically distinguished as the first aneuploid, continuously cultured human cell line established in 1951. Originally isolated from an epitheloid cervix carcinoma of a 31-year-old Black female (with a later updated diagnosis of adenocarcinoma), HeLa cells are characterized by their rapid proliferation and exceptionally stable growth profiles. Serving as a foundational model in cancer research, gene editing (e.g., CRISPR), and drug screening, this line also plays a critical role in virology due to its high susceptibility to Poliovirus type I and adenovirus type 3. Because of its robust growth advantage, HeLa has been frequently identified as a prominent cross-contaminant in numerous other cell lines, and therefore must be strictly managed and handled under laboratory containment level 2.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.